Skip to content
When it comes to enabling new treatments for type 1 diabetes (T1D), Breakthrough T1D is an outstanding example of a patient group driving research […]
Breaking barriers to a cure: Patient perspectives matter in type 1 diabetes innovation Read More »
Patents offer the intellectual property protections investors need to support biotech innovation. That’s why the Biotechnology Innovation Organization (BIO) annual IP Council and Committees
BIO 2025 IP Conference: Challenging times for the laws that drive innovation Read More »
November is National Family Caregivers Month, and to mark the occasion, Bio.News sat down with the National Alliance for Caregiving (NAC) to discuss the
National Family Caregivers Month: Recognizing 63 million Americans Read More »
Cancer patients are suffering serious health consequences because step therapy practices enforced by pharmacy benefit managers (PBMs) are preventing timely access to essential medicines,
Oncologist warns PBM step therapy has ‘crossed a dangerous line’ Read More »
Medicare’s 2026 Open Enrollment period for Part D plans began on Oct. 15 and runs through Dec. 7. “As patient advocates have seen year
BIO Coffee Chat: Guiding patients through Part D open enrollment Read More »
At a time when the biopharma industry is seeking to increase U.S. manufacturing, Indiana is in the vanguard—and still expanding. During a Nov. 11
BIO on the American Road: Indiana, a production powerhouse, is still expanding Read More »
Venture capital funding for life sciences startups plummeted after legal changes weakened the patent system, according to new research that confirms the close relationship
Ahead of BIO IP Conference, research highlights why biotech needs strong patents Read More »
Three years after the passage of the Inflation Reduction Act (IRA), patient advocates and the biotech industry are working to navigate downstream negative impacts
PACE: Downstream effects of IRA on patients Read More »
Luke Rosen had hoped a new treatment would slow the progression of his daughter’s KIF1A Associated Neurological Disorder (KAND), but was amazed to see
PACE panel urges incentives for exciting new GTT drugs Read More »
The 340B program, in recent decades, has shown how the best laid plans can go sideways when not kept transparent and properly in check.
PACE: How 340B outgrew its goal and stopped helping patients Read More »
